EPO and Huntington disease: 12 adult, chronic, stable HD patients, already under treatment with a thrice weekly IV rcEPO, were subjected to treatment scheme using regimes of IV and SC rcEPO  recombinant human EPO (rcEPO) injections in discrete phases to assess pharmacokinetics and therapeutic response to both routes. Serum analyses were carried out at specific time intervals for achieving the goals of this study.